At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ITRM Iterum Therapeutics Plc
Pre-Market Trading 01-24 07:31:18 EST
1.50
-0.02
-1.32%
盘前1.59
+0.09+6.00%
07:12 EST
High1.55
Low1.48
Vol471.00K
Open1.52
D1 Closing1.52
Amplitude4.45%
Mkt Cap41.27M
Tradable Cap40.16M
Total Shares27.52M
T/O708.90K
T/O Rate1.76%
Tradable Shares26.77M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Iterum Therapeutics Plc Files for Offering of up to $25 Mln of Ordinary Shares - SEC Filing
Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.